Clinical Trial: Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Myelofibrosis (PMF)
Study Type: INTERVENTIONAL
Official Title: Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]
Brief Summary:
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi).26 patients will be enrolled.Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6…
Read more